Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AuRico Gold Announces US$300M Share Buy-Back Through Substantial Issuer Bid
http://www.streetinsider.com/Press+Releases/AuRico+Gold+Announces+US%24300M+Share+Buy-Back+Through+Substantial+Issuer+Bid/7951868.html
TZYM Halts TZP-102 Phase 2b; Cites Insufficient Efficacy
http://www.streetinsider.com/Corporate+News/Tranzyme+(TZYM)+Halts+TZP-102+Phase+2b%3B+Cites+Insufficient+Efficacy/7951901.html
Half WS out in defence of AAPL
Must've had a call from Washington, national importance and all that. Back over $500 in PM.
CYCC Enters Into $20M Common Purchase Agreement
http://www.streetinsider.com/Corporate+News/Cyclacel+Pharma+(CYCC)+Entes+%2420M+Common+Purchase+Agreement/7951642.html
On December 14, 2012, Cyclacel Pharmaceuticals, Inc., a Delaware corporation (Nasdaq: CYCC), entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $20 million of shares of the Company’s common stock (the “Purchase Shares”) over the two-year term of the Purchase Agreement.
Concurrently with entering into the Purchase Agreement, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Aspire Capital, dated December 14, 2012. The Registration Rights Agreement provides, among other things, that the Company will file one or more registration statements, as necessary, to register under the Securities Act of 1933, as amended, the sale of the shares of common stock that have been and may be issued to Aspire Capital under the Purchase Agreement (collectively, the “Securities”). The Company agreed to file an initial registration statement registering the sale of the Securities by Aspire Capital with the Securities and Exchange Commission (the “SEC”) on or before January 9, 2013. The Company further agreed to keep the registration statement effective and to indemnify Aspire Capital for certain liabilities in connection with the sale of the Securities under the terms of the Registration Rights Agreement.
Kratos receives $4.2M in new equipment orders for a national security program
Kratos Defense & Security Solutions announced that it recently received new equipment orders related to a certain National Security program totaling $4.2M. These recent equipment orders bring the total value of all orders Kratos has received under this program over the past year to approximately $33M. The specialized equipment that Kratos is supplying under these recent awards is expected to be delivered in the first half of 2013. The equipment for which Kratos is under contract will be produced in a secure Kratos manufacturing facility. Due to the nature of the contract, security-related, customer specific and other considerations, no additional information will be provided regarding this program.
Lexicon Pharma drug candidate for IBS receives FDA fast track status
Up 16% in PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received "Fast Track" status from the U.S. Food and Drug Administration (FDA) for the development of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).
"We are pleased with the FDA's grant of Fast Track status for LX1033 in IBS-d, recognizing this important area of unmet medical need and the potential benefits that LX1033 could provide for those suffering from this disease," said Pablo Lapuerta, M.D., senior vice president and chief medical officer at Lexicon.
LX1033, an inhibitor of tryptophan hydroxylase (TPH) that acts locally in the gastrointestinal tract, is currently being evaluated in a Phase 2 clinical trial for IBS-d. The Phase 2 trial is a randomized, double-blind study designed to evaluate the safety and efficacy of LX1033 versus placebo in approximately 360 IBS-d patients, with results expected in the first half of 2013. LX1033 is a follow-on compound to LX1031, a previous-generation oral, locally-acting TPH inhibitor developed by Lexicon which had previously shown clinical benefit in a Phase 2 trial for IBS-d. Results from the LX1031 Phase 2 trial have been published in the journal Gastroenterology (2011; 141:507-516).
JA Solar commences solar module shipments from bids totaling 40MW
JA Solar Holdings Co., Ltd. (Nasdaq: JASO) has commenced solar module shipments from successful bids totaling 40MW with China Three Gorges New Energy Corporation ("CTGNE"). The Company has signed supply agreements with subsidiaries of CTGNE for 40MW of modules, delivery of which is expected to be completed by the end of 2012.
The modules will be used in a utility-scale project in Ningxia province, China, which will be connected to the province's power grid. The project will be the largest PV plant built in Ningxia in 2012 in terms of installed capacity.
Weeklies on watch
'Only' 14 :)
Obviously the metals:
X: shot past the 200MA. Lots of expectations now, if strength persists, think we're pretty clear till 25.13
CLF: plenty of resistance here, but may test the 50MA
WLT: past resistance and we've reached multi-top land. Several failed attempts, but if we do get past there, 200MA awaits.
ANR: slowly creeping towards the 200MA.
FCX: continue the gap fill or not?
Others
SLB: lowered outlook, lost the 200MA but did manage to find support and bounce back a bit. So near to the 200MA, it's bound to be a magnet.
FFIV: all that effort to crawl back up, and then it meets the downward TL and crashes. Saved on Thursday by the 20MA, crashed through the 50 & 20MA the next day. Found support @ 90. Should be interesting with both the 50MA & the TL pushing down.
WYNN: stuck in a pretty tight range, trying to break over $115 Good to see we've got a 2.5 interval in strike prices now.
LULU: multiple attempts to break $75, no luck so far. Needs that push or we get the usual pull-back.
CMG: going nowhere ATM. Perhaps with the 20MA pushing over the 50 we can get a decisive move.
PCLN: back over the 50MA, consolidation or back to $600?
Stalling for quite some time now.
CF: two days of whacking, from one TL to the other. 20/50MA overhead, so this may take a while to get back up there. Definitely one of last week's top plays.
JOY: tried the gap fill, but fell back. Lots of strength her with the close over the 200MA. That resistance line looks doable.
FCX even managed to stay just in gap fill land, not bad for a stock many thought would drift into 20s. Will be interesting to see where from here - we still got those questionable buyout offers.
As for non-runners, agree, was watching one of my favs this year, NAK, and no move. Steel/coal did well, though not all.
Ugh, CNBC, the Oracle.
Well, either way, think we are close to a pull-back, the run's been great. Profit vs. risk reward is low IMO, unless we get a huge push beyond $15.
I'd like to think that in stocks like RIMM volume is too big to be influenced by the like of SA & Fool, but who knows.
Yeah, I like that variety, shows a different way of thinking/scanning.
You been on fire, time for a few more Christmas plays. :)
Wow, what is this, a coordinated attack? Guess some people not happy with this rise from the dead.
On watch 12/17
Early Nov levels still being resistance after a few days of strong volume trading. Does look like it wants back up.
Gap fill started after a few failed attempts.
Right at the downward TL resistance. Last attempt in Sept. failed. 200MA @ 7.02 additional resistance & multi-top in 7.30s after that.
Past $30 and we continue the gap fill. Plenty of strength here.
At resistance after a few good days. Looking for $5.
Very strong volume for quite a few days now. Finally past the 20MA. 200MA @ 1.37.
Past downward TL resistance, now the 50MA. not the strongest of closes, but worth keeping an eye on.
Offering @ 2.85, but this one does like to run so we may see a recovery son.
Missed this one, was a nice option play too. Dropped after FDA approval, support @ 200MA. Granted, if you look at the weekly, the drop is virtually meaningless.
Trying, again.
Tricky stock, but did get past the 20 on volume. Really needs to show continuation.
Trying to find support @ 7.20
Double bottom @ 1.25
Past the 50MA on volume. Insider buying always helps.
Big volume block in the last trading hour.
LPR: +10%
Having another one of its fits.
KFS: +10%
Getting there :)
RIGL +11% into GF
CRME: +16%
Pretty sizeable pull-back; looking at the weekly, seems like it id a round trip to 9.89 and that was it.
Nice morning gains :)
STXS +35%
Guess the last hour was a signal...
The rate the PPS is going, Schulze is only winner in this dragging out. of course, you don't wanna be buying a company too deep down in the mud.
Extend extend extend. Just get this soap opera over with.
Another reason to be wary with holding these overnight.
Yeah, my mid 14s seem lower than most people's projections :) Almost January, should increase volatility too.
Edit: good morning to you too.
XOM Has its Rating Cut at Goldman Sachs
So far holding up above the 20MA.
Analyst at Goldman Sachs took the hatchet to major integrated oil company ExxonMobil (NYSE: XOM) Friday, cutting their rating from Buy to Neutral and their price target from $100 to $97.00. The firm cited a lower E&P outlook and an investors shift fo hiher beta names.
http://www.streetinsider.com/Analyst+PT+Change/ExxonMobil+(XOM)+Has+its+Rating+Cut+at+Goldman+Sachs/7948751.html
ACRX Reports Statistically Significant Data from NanoTab PCA Phase 3
Had a strong close yesterday:
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced that top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System, will be featured in poster presentations to be held at the 66th annual New York State Society of Anesthesiologists PostGraduate Assembly meeting in New York City to be held December 14-18, 2012. The poster is authored by Dr. Timothy Melson of Helen Keller Hospital, Sheffield, AL, Dr. Alparslan Turan of The Cleveland Clinic, Cleveland, OH, and Dr. Pamela Palmer of University of California, San Francisco, and Chief Medical Officer of AcelRx Pharmaceuticals and will be presented on Sunday, December 16, 2012 from 11:00 AM to 1:00 PM at the New York Marriott Marquis.
http://www.streetinsider.com/Corporate+News/AcelRx+(ACRX)+Reports+Statistically+Significant+Data+from+NanoTab+PCA+Phase+3/7948743.html
Europe's CHMP give positive opinion recommending authorization for Adasuve
Thx for that. Could indeed be a nice day, assuming the talking heads don't ruin it.
Nice one on GOK, cj, this time it went well into EOD.